Darmstadt, Merck KGaA, Pharmacology, Health care, Merck, Medicine
Merck KGaA, Darmstadt, Germany, Invests in State-Of-The-Art Biotech Development Facility in Switzerland
RT @iitoLifeScience: Merck Invests €250m in Biotech Development Facility in Switzerland https://t.co/X4vlCuWqMZ @merckgroup More DACH Region life science business news at [LSG] at
https://t.co/Rp09hmJoTQ https://t.co/phjTSFi5tH
OpenMerck KGaA, Darmstadt, Germany today announced an investment of €250 million euros in a new facility in Corsier-sur-Vevey, Switzerland – the Merck Biotech Development Center – dedicated to biotech development and manufacturing for clinical studies.
RT @iitoLifeScience: Merck Invests €250m in Biotech Development Facility in Switzerland https://t.co/X4vlCuWqMZ @merckgroup More DACH Region life science business news at [LSG] at
https://t.co/Rp09hmJoTQ https://t.co/phjTSFi5tH
OpenMerck KGaA, Darmstadt, Germany, Invests in State-Of-The-Art Biotech Development Facility in Switzerland
Merck KGaA, Darmstadt, Germany today announced an investment of €250 million euros in a new facility in Corsier-sur-Vevey, Switzerland – the Merck Biotech Development Center – dedicated to ...
We are sorry, we could not find the related article
If you are curious about Essentials, the Influencers Review and Swiss Innovation
Please click on:
Or signup to our newsletters
Merck invests €250 million to build biotechnology center in Switzerland
Merck KGaA (Darmstadt, Germany; www.merck.com) announced an investment of €250 million euros in a new facility in Corsier-sur-Vevey, Switzerland – the Merc
Merck Invests in State-of-the-art Biotech Development Facility in Switzerland
/PRNewswire/ -- Merck, a leading science and technology company, today announced an investment of €250 million euros in a new facility in Corsier-sur-Vevey,...
Merck to up drug product capacity by 50% at Swiss site
Merck KGaA will invest €150 million ($168 million) to build a facility with two new aseptic filling lines at its site in Aubonne. For Germany’s Merck, the Aubonne site in Switzerland is its ...
Sanofi's hard-hit Lemtrada goes under EU review for fatal side effects in heart, blood vessels
After a tough year in the competitive multiple sclerosis field, Sanofi’s Lemtrada could hardly afford another setback. But that’s exactly what it received last week. The EMA has recommended ...
Merck KGaA to Expand Aubonne, Switzerland Manufacturing Site
Merck KGaA, Darmstadt, Germany, will carry out a €150 million ($168 million) expansion of its biologics manufacturing site at Aubonne, Switzerland, designed to help meet growing demand for ...
Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors – Merck KGaA, Darmstadt, Germany Designates Undisclosed Bispecific ADC as ...
Merck KGaA, Darmstadt, Germany, Announces Collaboration with Iktos for Generative Artificial Intelligence (AI) Technology
Merck KGaA, Darmstadt, Germany today announced a collaboration agreement with Iktos, for the use of its generative modelling artificial intelligence (AI) technology
Just Filed for IND? What Now?
Throughout drug discovery and development, emerging biotech companies often find themselves in the predicament of having to balance costs, speed, and risks. Though inadvisable, many ...
PureTech bags $200M from sale of Karuna shares — still sizzling from promising schizophrenia data
Cashing in on the exuberance around Karuna Therapeutics and its potential blockbuster CNS drug, PureTech has sold a chunk of the biotech’s shares to Goldman Sachs for $200 million. ...
Merck invests €150 million in Switzerland
To increase production of its biotech medicines, Merck has Invested will see the Aubonne site increase production of biotech medicines raising the locations profile as a manufacturing hub
At the forefront of pediatric drug development
Having conducted 95 + pediatric clinical trials, our expert team is at the forefront of developing customized pediatric clinical research and drug development plans.